此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Exploring the Efficacy and Mechanism of Accelerated High-Definition Transcranial Direct Current Stimulation (HD-tDCS) in the Treatment of Obsessive-compulsive Disorder

2026年11月11日 更新者:Zhen Wang、Shanghai Mental Health Center

Exploring the Efficacy and Mechanism of Accelerated High-Definition Transcranial Direct Current Stimulation (HD-tDCS) in the Treatment of Obsessive-compulsive Disorder: A Randomized Controlled Trial

This study will evaluate the therapeutic effects of accelerated high-definition transcranial direct current stimulation (HD-tDCS) as adjunct to pharmacotherapy in obsessive-compulsive disorder (OCD) patients, and the underlying neural mechanism by EEG, MRI, TMS-EEG and cognitive tasks.

研究概览

详细说明

The purpose of this study is to evaluate the clinical efficacy of accelerated high-definition transcranial direct current stimulation (HD-tDCS) targeting the orbitofrontal cortex (OFC) as an adjunct to pharmacotherapy in patients with obsessive-compulsive disorder (OCD), and to investigate its underlying neural mechanisms. Sixty patients with OCD receiving stable pharmacotherapy will be randomized to receive either active or sham HD-tDCS. Stimulation will be administered four times daily for five consecutive days, followed by a two-day break and another five consecutive days of treatment, for a total of 40 sessions. Before each stimulation session, symptom provocation will be conducted by a research assistant who has completed standardized training.

Symptom severity will be assessed at baseline and upon completion of the HD-tDCS intervention. Assessments conducted throughout the study will include the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), the Clinical Global Impression (CGI) scale, the Obsessive-Compulsive Inventory-Revised (OCI-R), the Beck Depression Inventory-II (BDI-II), the Beck Anxiety Inventory (BAI), the Childhood Trauma Questionnaire (CTQ), a side-effect questionnaire, and other study-specified measures. A trained investigator will administer clinician-rated measures and oversee the completion of self-report questionnaires. Participants will also undergo magnetic resonance imaging (MRI), electroencephalography (EEG), and transcranial magnetic stimulation combined with EEG (TMS-EEG).

The Iowa Gambling Task will be administered at baseline, upon completion of the HD-tDCS intervention, and at the one-month follow-up after intervention completion to assess decision-making performance. The probabilistic reversal learning task will be administered at baseline, after the first HD-tDCS session, upon completion of the intervention, and at the one-month follow-up to assess reversal learning and cognitive flexibility under probabilistic uncertainty.

研究类型

介入性

注册 (估计的)

60

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国
        • Shanghai Mental Health Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 50年 (成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Aged 18-50 years, of Han Chinese ethnicity, and right-handed.
  2. Meet the diagnostic criteria for obsessive-compulsive disorder (OCD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).
  3. Have a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score ≥16.
  4. Have received at least one selective serotonin reuptake inhibitor (SSRI) at an adequate dose for an adequate duration. If currently taking medication, the dose must have been stable for at least eight weeks, and the medication type and dose must remain unchanged throughout the study.
  5. Have completed junior high school education or above.
  6. Provide informed consent.

Exclusion Criteria:

  1. Meet DSM-5 diagnostic criteria for a psychiatric disorder other than OCD, as assessed using the Structured Clinical Interview for DSM-5 (SCID-5).
  2. Have obsessive-compulsive symptoms severe enough to prevent completion of the required assessments and examinations.
  3. Have received electroconvulsive therapy (ECT), including modified ECT, within the past six months, or any other form of neuromodulation within the past two months.
  4. Have a serious medical condition or any medical condition that may precipitate seizures or increased intracranial pressure, including cardiovascular or respiratory diseases.
  5. Have a history of neurological disorders (e.g., epilepsy or stroke), traumatic brain injury, or brain surgery.
  6. Have implanted medical devices or materials, such as intracranial stents, cardiac pacemakers, coronary stents, or cochlear implants.
  7. Be at high risk of suicide.
  8. Be pregnant or planning to become pregnant in the near future.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
有源比较器:active HD-tDCS

Active cathodal high-definition transcranial direct current stimulation (HD-tDCS) targeting the right orbitofrontal cortex (OFC) will be administered four times daily at two-hour intervals for five consecutive days, followed by a two-day break and another five consecutive days of treatment, for a total of 40 sessions. Before each stimulation session, symptom provocation will be conducted by a research assistant who has completed standardized training.

The HD-tDCS device will deliver a direct current of 2 mA for 20 minutes per session. The cathode will be positioned at Fp2 to target the right orbitofrontal cortex (OFC), with four return anodes placed at Fpz, AFz, AF4, and AF8, according to the international 10-10 EEG electrode placement system.

假比较器:sham HD-tDCS

Sham high-definition transcranial direct current stimulation (HD-tDCS) targeting the right orbitofrontal cortex (OFC) will be administered four times daily at two-hour intervals for five consecutive days, followed by a two-day break and another five consecutive days of treatment, for a total of 40 sessions. Before each stimulation session, symptom provocation will be conducted by a research assistant who has completed standardized training.

In the sham stimulation group, the current will be gradually ramped up to 2 mA over approximately 30 seconds at the beginning of each session and ramped down to 0 mA over approximately 30 seconds at the end of each session.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Symptom improvement assessed by the Yale-Brown Obsessive Compulsive Scale(Y-BOCS)
大体时间:About 6 weeks

The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) is a semi-structured, clinician-rated instrument used to assess the severity of obsessive-compulsive symptoms. It comprises 10 items: five assessing obsessions and five assessing compulsions. Each item is rated on a five-point scale from 0 to 4, yielding a total score ranging from 0 to 40, with higher scores indicating greater symptom severity. Treatment response is defined as a reduction of at least 35% in the Y-BOCS total score from baseline to the end of the HD-tDCS intervention.

About 6 weeks

次要结果测量

结果测量
措施说明
大体时间
The Beck Depression Inventory-II (BDI-II)
大体时间:About 6 weeks

It is a 21-item self-report measure scored on a 4-point Likert-type scale to summarize recent symptoms of depression.The higher the score, the higher the level of depression.

About 6 weeks
The Beck Anxiety Inventory (BAI)
大体时间:About 6 weeks

It is a 21-item self-report inventory that is used for measuring the severity of anxiety.The higher the score, the higher the level of anxiety.

About 6 weeks
Side-effect questionnaire
大体时间:About 6 weeks

It consists of ten commonly-reported side effects as well as an "other" category that allows participants to describe experiences/sensations not otherwise covered to rate the intensity of side effects.

About 6 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月25日

初级完成 (估计的)

2029年10月31日

研究完成 (估计的)

2029年12月31日

研究注册日期

首次提交

2026年11月11日

首先提交符合 QC 标准的

2026年11月11日

首次发布 (实际的)

2026年11月17日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月11日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • 20240XJQ03DCS

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅